"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

Incyte Corp.’s mention of would-be “backup molecules” could bode well for findings yet to roll out with Mas-related G protein-coupled receptor X2 antagonist INCB-000262 in chronic spontaneous ...

Opens in a new tab or window The study was broken into two groups of patients: patients who had a history of cold-induced urticaria, and this is diagnosed by either something called a TempTest ...

Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). Consequently, shares of Incyte were down 9% on Nov. 18 in after-market ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

The addition of dupilumab significantly reduced itching and hives compared with placebo in patients with chronic spontaneous urticaria (CSU) that was uncontrolled with H1-antihistamines ...